Cargando…

Spondyloarthritis: How far are we from precision medicine?

Spondyloarthritis (SpA) is a family of heterogenous diseases consisting of different phenotypes. The exact disease mechanism remains unclear but evidence shows the complex pathophysiology with interplay between genome, microbiome, and immunome. Biologic DMARDs have markedly improved patients' d...

Descripción completa

Detalles Bibliográficos
Autores principales:	So, Jacqueline, De Craemer, Ann-Sophie, Elewaut, Dirk, Tam, Lai-Shan
Formato:	Online Artículo Texto
Lenguaje:	English
Publicado:	Frontiers Media S.A. 2022
Materias:	Medicine
Acceso en línea:	https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9492940/ https://www.ncbi.nlm.nih.gov/pubmed/36160128 http://dx.doi.org/10.3389/fmed.2022.988532

Ejemplares similares

Precision Medicine in Solid Tumors: How Far We Traveled So Far?
por: Dey, Nandini, et al.
Publicado: (2022)

Inflammatory Foot Involvement in Spondyloarthritis: From Tarsitis to Ankylosing Tarsitis
por: Romero-López, José Pablo, et al.
Publicado: (2021)

The role of metabolomics in precision medicine of osteoarthritis: How far are we?
por: Zhai, Guangju
Publicado: (2021)

In vitro triple coculture with gut microbiota from spondyloarthritis patients is characterized by inter-individual differences in inflammatory responses
por: Beterams, Annelore, et al.
Publicado: (2022)

Extent of axial damage in psoriatic arthritis and spondyloarthritis: comparative data from the BEPAS and (Be-)GIANT multicentre cohorts
por: de Hooge, Manouk, et al.
Publicado: (2023)

Gut Microbiome and Its Interaction with Immune System in Spondyloarthritis
por: So, Jacqueline, et al.
Publicado: (2020)

How far can we go in precision with ALR?
por: Blondel, A
Publicado: (1990)

Toward Precision Medicine: How Far Is the Goal?
por: Ravegnini, Gloria, et al.
Publicado: (2016)

Peripheral spondyloarthritis: a neglected entity—state of the art
por: Carron, Philippe, et al.
Publicado: (2020)

Progress in spondylarthritis. Immunopathogenesis of spondyloarthritis: which cells drive disease?
por: Melis, Lode, et al.
Publicado: (2009)

How Far Are We from Prescribing Fasting as Anticancer Medicine?
por: Deligiorgi, Maria V., et al.
Publicado: (2020)

Anti-IL17A in Axial Spondyloarthritis—Where Are We At?
por: Cheung, Peter P.
Publicado: (2017)

Monocyte transcriptomes from patients with axial spondyloarthritis reveal dysregulated monocytopoiesis and a distinct inflammatory imprint
por: Karow, Fabian, et al.
Publicado: (2021)

Comorbidities in Spondyloarthritis
por: Moltó, Anna, et al.
Publicado: (2018)

How Far Will We See in the Future?
por: Nasmyth, Kim
Publicado: (2010)

Milestones in Heart Failure: How Far We Have Come and How Far We Have Left to Go
por: Gajjela, Harini, et al.
Publicado: (2021)

Paediatric Surgery on the African Continent: How Far Have We Come; How Far Can We Go?
por: Numanoglu, Alp
Publicado: (2023)

Neuro-Nutraceutical Polyphenols: How Far Are We?
por: Gentile, Maria Teresa, et al.
Publicado: (2023)

From Science to Success? Targeting Tyrosine Kinase 2 in Spondyloarthritis and Related Chronic Inflammatory Diseases
por: Hromadová, Dominika, et al.
Publicado: (2021)

Thermophilic biohydrogen production: how far are we?
por: Pawar, Sudhanshu S., et al.
Publicado: (2013)

How Far Can We Hear with the Telephone?
Publicado: (1879)

Omics in Clinical Practice: How Far Are We?
por: Sáez, María Eugenia
Publicado: (2022)

Obesity and Dose of Anti-cancer Therapy: Are We Sure to Be on the Right Track in the Precision Medicine Era?
por: Rossi, Tania, et al.
Publicado: (2021)

Immunotherapy in myeloma: how far have we come?
por: Franssen, Laurens E., et al.
Publicado: (2019)

Place Identity: How Far Have We Come in Exploring Its Meanings?
por: Peng, Jianchao, et al.
Publicado: (2020)

Classifications and imaging of juvenile spondyloarthritis
por: Sudoł-Szopińska, Iwona, et al.
Publicado: (2018)

Outcomes in Juvenile-Onset Spondyloarthritis
por: Smith, Judith A., et al.
Publicado: (2021)

Model validity for preclinical studies in precision medicine: precisely how precise do we need to be?
por: Tadenev, Abigail L. D., et al.
Publicado: (2019)

Carotid Artery Calcification: What We Know So Far
por: Ahmed, Madeeha, et al.
Publicado: (2021)

Rational Design of Topical Semi-Solid Dosage Forms-How Far Are We?
por: Herbig, Michael E., et al.
Publicado: (2023)

Juvenile Spondyloarthritis: What More Do We Know About HLA-B27, Enthesitis, and New Bone Formation?
por: Tay, Shi Huan, et al.
Publicado: (2021)

Transcatheter Bioprosthetic Aortic Valve Dysfunction: What We Know So Far
por: Sawaya, Fadi, et al.
Publicado: (2019)

Prevention of diabetes: How far have we gone?
por: Ramachandran, Ambady, et al.
Publicado: (2014)

How Far Are We Justified in Anticipating Proximate Decay?
por: Swain, E. D.
Publicado: (1875)

Editorial: Sirtuins From Bench to Bedside: How Far Are We?
por: Thaiparambil, Jose
Publicado: (2022)

Fairness-aware machine learning engineering: how far are we?
por: Ferrara, Carmine, et al.
Publicado: (2023)

The Role of Imaging in Diagnosing Axial Spondyloarthritis
por: Khmelinskii, Nikita, et al.
Publicado: (2018)

Editorial: Radiographic progression in axial spondyloarthritis
por: Pimentel-Santos, F. M., et al.
Publicado: (2023)

Computed tomography-based assessment of radiographic progression in spine and sacroiliac joints after pregnancy in women with radiographic axial spondyloarthritis
por: Lee, Kyung-Ann, et al.
Publicado: (2022)

From Big Data to Precision Medicine
por: Hulsen, Tim, et al.
Publicado: (2019)

Cannot write session to /tmp/vufind_sessions/sess_hcr3ppqg2t338ld8k02ij1og5j